Skip to main content

Table 2 Identification of tissue-enrichment terms and biological processes associated with selected genes dysregulated in blood of PD patients versus controls

From: Blood transcriptomics of drug-naïve sporadic Parkinson’s disease patients

Category Term Count Percent P-Value Benjamini
UP TISSUE Brain 141 50.00 7.4E-3 7.1E-1
UP TISSUE Testis 70 24.08 1.9E-2 8.0E-1
UP TISSUE Epithelium 59 20.09 3.2E-2 8.4E-1
UP TISSUE Lymphoma 4 1.04 6.1E-2 9.3E-1
UP TISSUE Testicle 3 1.01 7.4E-2 9.2E-1
GOTERM_BP_FAT ncRNA processing 10 3.05 4.2E-3 1.0E0
GOTERM_BP_FAT regulation of gene expression, epigenetic 6 2.01 1.1E-2 1.0E0
GOTERM_BP_FAT lymphocyte activation 10 3.05 1.3E-2 1.0E0
GOTERM_BP_FAT lipid homeostasis 5 1.08 1.5E-2 1.0E0
GOTERM_BP_FAT chromatin assembly or disassembly 7 2.05 1.7E-2 9.9E-1
GOTERM_BP_FAT midbrain development 3 1.01 2.0E-2 9.9E-1
GOTERM_BP_FAT chemical homeostasis 17 6.00 2.9E-2 1.0E0
GOTERM_BP_FAT negative regulation of protein kinase cascade 4 1.04 3.0E-2 1.0E0
GOTERM_BP_FAT ncRNA metabolic process 9 3.02 3.5E-2 1.0E0
GOTERM_BP_FAT regulation of action potential 5 1.08 3.8E-2 1.0E0
GOTERM_BP_FAT leukocyte activation 10 3.05 3.9E-2 1.0E0
GOTERM_BP_FAT cell activation 11 3.09 4.2E-2 1.0E0
  1. a)Tissue enrichment analysis. Count: number of genes involved in the term; %: percentage of involved genes/total genes; P-Value: modified fisher exact P-value, EASE Score; Benjamini: adjusted P-value using Benjamini-Hochberg procedure. b)Biological processes identified by GO annotations (DAVID)